PF-04971729 (Ertugliflozin): A Benchmark SGLT2 Inhibitor for Diabetes and Renal Glucose Transport Research

Executive Summary: Ertugliflozin (PF-04971729, SKU A3715) is a potent oral sodium-glucose co-transporter 2 (SGLT2) inhibitor with >2000-fold selectivity for SGLT2 over SGLT1, enabling targeted studies on renal glucose reabsorption (product_spec). In clinical trials, it reduced glycated hemoglobin and body weight, and showed a hazard ratio of 0.88 for cardiovascular death or heart failure hospitalization compared to placebo (Cannon et al., 2020). Ertugliflozin is soluble in DMSO and ethanol but insoluble in water, facilitating in vitro and in vivo protocols (product_spec). It mediates anti-inflammatory, renal-protective, and mucosal repair effects in disease models. Protocols typically employ 1–10 mg/kg/day in animals and 5–15 mg once daily in humans (product_spec).

Biological Rationale

Diabetes mellitus type 2 (T2D) is characterized by chronic hyperglycemia and increased risk of cardiovascular and renal complications (Cannon et al., 2020). The kidneys play a central role in glucose homeostasis through SGLT2-mediated reabsorption in the proximal tubules. Selective inhibition of SGLT2 promotes glycosuria, lowering blood glucose independently of insulin action. The development of SGLT2 inhibitors like Ertugliflozin enables highly targeted modulation of the renal glucose transport pathway, advancing both mechanistic research and translational protocols (internal).

Mechanism of Action of Ertugliflozin (PF-04971729)

Ertugliflozin specifically targets the sodium-dependent glucose cotransporter 2 (SGLT2), which is responsible for approximately 90% of glucose reabsorption in the proximal renal tubule (Cannon et al., 2020). The compound exhibits >2000-fold selectivity for SGLT2 over SGLT1, minimizing off-target effects (product_spec). By blocking SGLT2-mediated glucose uptake, Ertugliflozin increases urinary glucose excretion and reduces plasma glucose levels. Mechanistically, it is also reported to inhibit the NF-κB pathway, downregulate miR-155 expression, and promote M2 macrophage polarization in inflammatory models, supporting research beyond glycemic endpoints (product_spec).

Evidence & Benchmarks

• In a multicenter, double-blind clinical trial (VERTIS CV), Ertugliflozin was noninferior to placebo regarding major adverse cardiovascular events, with a hazard ratio of 0.97 (95.6% CI, 0.85 to 1.11) (Cannon et al., 2020).
• The rate of death from cardiovascular causes or hospitalization for heart failure was 8.1% in the Ertugliflozin group versus 9.1% for placebo (hazard ratio 0.88; 95.8% CI, 0.75 to 1.03) (Cannon et al., 2020).
• Hazard ratio for death from renal causes, renal replacement therapy, or doubling of serum creatinine was 0.81 (95.8% CI, 0.63 to 1.04) (Cannon et al., 2020).
• Ertugliflozin administered orally at 5 mg or 15 mg once daily achieves significant reductions in HbA1c and body weight in T2D patients (Cannon et al., 2020).
• Preclinical models demonstrate 10 mg/kg/day oral dosing yields efficacy comparable to sulfasalazine in ulcerative colitis models (product_spec).
• The compound is soluble at ≥50.8 mg/mL in DMSO and ≥51.5 mg/mL in ethanol, but insoluble in water (product_spec).
• Ertugliflozin's molecular weight is 436.88 g/mol, and it is supplied at ≥98% purity by APExBIO (product_spec).

This article extends Advanced Insights into SGLT2 by providing quantitative clinical benchmarks and protocol solubility data, clarifying translational endpoints for diabetes and renal research. For stepwise experimental design and troubleshooting, this workflow article offers protocol integration details, while the present review summarizes cross-model efficacy and clinical safety endpoints.

Applications, Limits & Misconceptions

Ertugliflozin (PF-04971729) is widely used in diabetes mellitus research, renal glucose transport assays, and as a reference compound for SGLT2-mediated glucose transport pathway interrogation. Its high selectivity and favorable pharmacokinetics enable robust in vitro and in vivo studies. The compound also supports research on cardiovascular protection and mucosal repair in inflammatory models. However, translation from preclinical to human outcomes requires attention to dose scaling and metabolic differences (internal).

Common Pitfalls or Misconceptions

• Ertugliflozin is not effective in SGLT2-knockout models, as its action is strictly SGLT2-dependent (product_spec).
• The compound is insoluble in water; protocols requiring aqueous solubility must use DMSO or ethanol as vehicles (product_spec).
• Clinical efficacy in glycemic control does not imply equivalent anti-inflammatory effects in all disease models; such claims require specific supporting evidence (Cannon et al., 2020).
• Not all cardiovascular endpoints are improved; superiority over placebo for major adverse cardiovascular events was not established, only noninferiority (Cannon et al., 2020).
• Long-term storage of prepared solutions is not recommended due to potential compound degradation (product_spec).

Workflow Integration & Parameters

Protocol Parameters

• in vivo rodent model | 1–10 mg/kg/day oral | preclinical efficacy and mechanistic studies | Dose range validated for efficacy and selectivity in diabetes and colitis models | product_spec
• clinical human T2D studies | 5 mg or 15 mg once daily oral | glycemic and cardiovascular endpoints | Doses shown to lower HbA1c and body weight, with 15 mg providing greater weight loss | DOI: https://doi.org/10.1056/NEJMoa2004967
• solubility assay | ≥50.8 mg/mL in DMSO; ≥51.5 mg/mL in ethanol; insoluble in water | solution preparation for in vitro/in vivo | Ensures protocol compatibility and reproducibility | product_spec
• storage | -20°C, avoid long-term solution storage | compound integrity | Minimizes degradation and maintains purity | product_spec
• renal glucose transport in vitro | 0.1–10 μM | SGLT2-mediated uptake assays | Range based on transporter affinity and selectivity | workflow_recommendation

For actionable guidance and scenario-driven troubleshooting, see this Q&A resource, which details APExBIO's recommended protocols and sourcing strategies for PF-04971729.

Conclusion & Outlook

Ertugliflozin (PF-04971729) remains a reference SGLT2 inhibitor for diabetes mellitus research, offering high selectivity, robust solubility parameters, and validated clinical and preclinical efficacy endpoints (Cannon et al., 2020). As supplied by APExBIO, its defined purity and storage profile support reproducible results across research domains. Future studies may further delineate its anti-inflammatory and mucosal repair mechanisms, but current evidence supports its use within the boundaries of SGLT2-mediated glucose transport and associated cardiometabolic effects. For advanced mechanistic studies and translational applications, the A3715 kit and referenced workflow articles remain valuable resources (APExBIO).